查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1465961

下一代癌症诊断市场：按技术、癌症类型、应用、功能划分 - 2024-2030 年全球预测

Next-Generation Cancer Diagnostics Market by Technology, Cancer Type, Application, Function - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

下一代癌症诊断市场规模预计到2023年为97.7亿美元，到2024年达到120.2亿美元，预计到2030年将达到443.6亿美元，复合年增长率为24.12%。

调查方法包括用于检测和表征癌症的工具、技术和方法的最新技术进步。该市场专注于与传统诊断方法相比提高准确性、灵敏度和特异性的技术创新。其中包括用于早期检测、预后预测和癌症治疗监测的基因组学、表观基因、表观基因组学、成像技术和生物资讯学工具。下一代癌症诊断的扩展是由多种因素推动的，包括全球癌症发病率的增加、基因组测序技术的进步以及对个人化医疗的日益重视。此外，政府的措施和癌症研究资助也对市场成长做出了重大贡献。将人工智慧和机器学习融入诊断也为提高癌症检测和预后的准确性提供了机会。儘管市场开拓广阔，但下一代癌症诊断市场仍面临一些限制和挑战。先进诊断技术的高成本可能会限制这些工具的使用，特别是在低收入和中等收入国家。此外，癌症生物学的复杂性和肿瘤类型的多样性对开发普遍有效的诊断解决方案提出了挑战。监管障碍和强大的临床检验的需求也减缓了市场创新的步伐。然而，液态切片、循环肿瘤 DNA (ctDNA) 分析和非侵入性成像技术等最新发展为早期癌症检测和监测开闢了新途径。这些进步代表着市场成长的巨大机会。此外，次世代定序仪（NGS）在癌症诊断中的应用不断发展，为发现新的生物标记和治疗标靶提供了潜力。

主要市场统计
基准年[2023] 97.7亿美元
预测年份 [2024] 120.2亿美元
预测年份 [2030] 443.6亿美元
复合年增长率（%） 24.12%

技术 对识别与癌症相关突变的分子诊断的需求增加

簇状规则间隔短回文重复诊断技术为癌症诊断提供了一种革命性的方法，利用基因编辑功能来准确检测癌症突变。该技术提供了快速、准确且经济高效的诊断潜力，从根本上改变了癌症的识别和治疗方式。 DNA 微阵列可以在一次实验中同时分析数千个 DNA 序列。该技术用于癌症诊断，以识别不同癌症类型特异性的基因突变和表达，从而促进个人化治疗计划。晶片实验室将多个测试步骤整合到一个晶片中，为癌症诊断提供了紧凑而高效的解决方案。当与 RT-PCR（一种测量基因表现的方法）结合时，它成为在分子层面上检测和量化癌症标记的强大工具。分子诊断分析 DNA 和 RNA 的碱基序列以识别与癌症相关的突变。该领域强调遗传分析在癌症早期检测、分类和管理中的重要性，并提供量身定制的治疗方法。 NGS 透过序列测定百万个 DNA 片段来提供全面的基因组分析。该技术可以深入了解导致癌症的基因突变，从而能够确定标靶治疗并改善患者的治疗结果。蛋白质微阵列大规模分析蛋白质表现和相互作用。在癌症诊断中，它用于研究癌症引起的蛋白质变化，有助于发现用于早期检测和治疗策略的新生物标记。定量聚合酵素链锁反应(qPCR) 是一种扩增和定量目标 DNA 分子的技术。多重分析可同时测量多种分析物，增强了 qPCR 在癌症诊断中的能力，让单次测试检测与癌症相关的多个基因。

应用范例 在治疗监测中部署诊断工具以追踪癌症治疗的有效性

癌症筛检是对抗癌症的第一道防线，利用下一代诊断技术来识别没有明显症状的人是否患有癌症。该领域专注于癌症的早期检测，旨在在治疗最有可能成功的阶段诊断疾病。先进的影像技术、分子诊断和生物标记评估是用于提高癌症筛检有效性的工具。伴同性诊断是专门的测试，旨在识别最有可能从标靶治疗中受益的患者。该领域透过确定预测患者对标靶治疗的反应的特定遗传和分子标记的存在，在个人化医疗中发挥重要作用。在下一代癌症诊断的背景下，基因组分析通常用于针对个别癌症制定治疗策略。下一代癌症诊断的预后工具用于预测诊断患者的癌症病程和结果。该领域有助于评估疾病侵袭性、復发风险和整体存活率预测。透过利用先进的基因组和蛋白质组分析，预后诊断药物支持有关治疗性介入的需求和强度的明智决策，最终指导患者管理计划。下一代癌症诊断的风险分析着重于根据遗传、环境和生活方式因素评估个体患癌症的风险。该领域使用各种基因测试和生物标记评估方法来识别患有某些癌症的高风险个体，从而有可能采取有针对性的预防措施和更频繁、​​更详细的监测计划。治疗监测使用下一代诊断工具来追踪癌症治疗的有效性并监测疾病进展或復发征兆。此应用领域对于即时调整治疗计划、管理副作用和改善患者治疗效果至关重要。透过使用循环肿瘤 DNA (ctDNA)、成像技术和其他生物标记物，治疗监测可以详细了解肿瘤对治疗的反应，并促进个人化治疗调整。

区域洞察

美国，特别是美国，透过对研发的大量投资正在取得快速进展。重点主要是精准医学和非侵入性诊断技术，例如用于检测循环肿瘤 DNA 的液态切片。欧洲、中东和非洲地区在下一代癌症诊断的采用和开发方面呈现出多样化的景象。欧洲在该地区处于领先地位，在强大的医疗保健系统和公共卫生政策的支持下，一些国家支持将基因序列测定和生物标记分析整合到标准癌症治疗中。中东，特别是以色列和阿拉伯联合大公国等国家，正迅速崛起为包括癌症诊断在内的医疗技术创新中心。非洲面临更多挑战，包括资源限制，但透过国际伙伴关係和改善癌症护理基础设施和可近性的努力正在取得进展。由于癌症发病率上升、医疗保健支出增加以及早期癌症检测意识的提高，亚太地区下一代癌症诊断市场正在经历显着增长。日本、韩国、中国和澳洲处于领先地位，在医疗保健技术和研究方面投入大量资金。特别是在中国，利用人工智慧的诊断工具等技术正在迅速发展，并表现出很高的采用率。除其他福利外，该地区受益于快速发展的生物技术新兴企业以及全球和本地公司之间旨在根据当地特点定制癌症诊断的战略联盟。

FPNV定位矩阵

FPNV 定位矩阵对于评估下一代癌症诊断市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对下一代癌症诊断市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.下一代癌症诊断市场的市场规模与预测为何？

2.在下一代癌症诊断市场的预测期内，需要考虑投资的产品、细分市场、应用和领域有哪些？

3.下一代癌症诊断市场的技术趋势和法规结构是什么？

4.下一代癌症诊断市场主要厂商的市场占有率为何？

5.进入下一代癌症诊断药物市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症患者数量不断增加，提高了对有效诊断的需求。
      • 扩大微流体控晶片在癌症治疗的应用
      • 政府癌症筛检倡议
    • 抑制因素
      • 诊断投资高且标准化不足
    • 机会
      • 个人化/先进基因组医学的普及
      • 下一代癌症诊断的技术进步
    • 任务
      • NGC 诊断相关的局限性和风险
  • 市场区隔分析
    • 技术：对分子诊断的需求增加，以识别与癌症相关的突变
    • 应用：在治疗监测中部署诊断工具来追踪癌症治疗效果
  • 市场趋势分析
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析
  • 客户客製化

第六章下一代癌症诊断市场：依技术分类

  • 丛集规则间隔短回文重复的诊断
  • DNA微阵列
  • 实验室晶片和逆转录 PCR
  • 分子诊断
  • 次世代定序
  • 蛋白质微阵列
  • qPCR 和多重检测

第7章按癌症类型分類的下一代癌症诊断药物市场

  • 膀胱癌
  • 乳癌
  • 子宫颈癌
  • 大肠直肠癌
  • 肾癌
  • 肺癌
  • 胰臟癌
  • 摄护腺癌
  • 甲状腺癌
  • 子宫癌

第八章下一代癌症诊断市场：按应用分类

  • 癌症筛检
  • 伴同性诊断
  • 预言
  • 风险分析
  • 治疗监测

第 9 章下一代癌症诊断市场：按功能分类

  • 生物标誌物开发
  • CTC分析
  • 表观遗传分析
  • 遗传分析
  • 蛋白质体分析

第十章 北美和南美下一代癌症诊断药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区下一代癌症诊断药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的下一代癌症诊断药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Genialis 开发基于生物标记的癌症诊断模型
    • Thermo Fisher Scientific 与 Arsenal Biosciences 合作支持自体 T 细胞疗法的临床生产
    • 辉瑞430亿美元收购Seagen并将重心转向肿瘤学
    • Ibex 和 Albano Laboratories 签署癌症诊断人工智慧的多年、多组织扩展协议
    • 斯旺西生物科技新兴企业筹集了 150 万英镑用于人工智慧结肠癌血液检测
    • 医疗保健精准医学透过下一代筛检加速精准肿瘤学并支持新的癌症诊断

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-AD36CD898567

[187 Pages Report] The Next-Generation Cancer Diagnostics Market size was estimated at USD 9.77 billion in 2023 and expected to reach USD 12.02 billion in 2024, at a CAGR 24.12% to reach USD 44.36 billion by 2030.

The next-generation cancer diagnostics market encompasses the latest technological advancements in the tools, techniques, and methodologies utilized to detect and characterize cancers. This market focuses on innovations that offer enhanced accuracy, sensitivity, and specificity compared to traditional diagnostic methods. It includes genomic, proteomic, and epigenomic analysis, imaging techniques, and bioinformatics tools for early detection, prognosis, and cancer treatment monitoring. Several factors drive the expansion of next-generation cancer diagnostics, including the increasing global prevalence of cancer, advancements in genomic sequencing technologies, and the growing emphasis on personalized medicine. Furthermore, government initiatives and funding for cancer research contribute significantly to market growth. Integrating artificial intelligence and machine learning in diagnostics also presents opportunities for enhanced precision in cancer detection and prognosis. Despite the promising development, the next-generation cancer diagnostics market faces several limitations and challenges. High costs associated with advanced diagnostic technologies can limit access to these tools, particularly in low- and middle-income countries. Moreover, the complexity of cancer biology and the variability in tumor types pose challenges in developing universally effective diagnostic solutions. Regulatory hurdles and the need for robust clinical validation also slow down the market's pace of innovation. However, recent developments in liquid biopsy, circulating tumor DNA (ctDNA) analysis, and non-invasive imaging techniques have opened new avenues for early cancer detection and monitoring. These advancements present significant opportunities for market growth. Moreover, the application of next-generation sequencing (NGS) in cancer diagnostics continues to evolve, offering the potential to discover novel biomarkers and therapeutic targets.

KEY MARKET STATISTICS
Base Year [2023] USD 9.77 billion
Estimated Year [2024] USD 12.02 billion
Forecast Year [2030] USD 44.36 billion
CAGR (%) 24.12%

Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer

Clustered regularly interspaced short palindromic repeats diagnostics technology presents a revolutionary approach to cancer diagnostics, leveraging its gene editing capabilities to detect cancer mutations precisely. This technique offers the potential for rapid, accurate, and cost-effective diagnostics, fundamentally changing how cancers are identified and treated. DNA microarrays enable the simultaneous analysis of thousands of DNA sequences in a single experiment. This technology is used in cancer diagnostics to identify gene mutations and expressions specific to different cancer types, facilitating personalized treatment plans. Lab-on-a-chip integrates multiple laboratory processes into a single chip, offering a compact and efficient solution for cancer diagnostics. Combined with RT-PCR, a method that measures gene expression, it provides a powerful tool for detecting and quantifying cancer markers at the molecular level. Molecular diagnostics involves analyzing DNA or RNA sequences to identify cancer-related mutations. This segment emphasizes the importance of genetic analysis in the early detection, classification, and management of cancer, offering a tailored approach to therapy. NGS offers comprehensive genomic profiling by sequencing millions of DNA fragments in parallel. This technology provides deep insights into the genetic mutations that cause cancer, allowing for the identification of targeted therapies and better outcomes for patients. Protein microarrays analyze the expression and interaction of proteins on a large scale. In cancer diagnostics, they are used to study protein changes caused by cancer, aiding in discovering new biomarkers for early detection and treatment strategies. Quantitative Polymerase Chain Reaction (qPCR) is a technique that amplifies and quantifies a targeted DNA molecule. Multiplexing, simultaneously measuring multiple analytes, enhances qPCR's capability in cancer diagnostics, allowing for detecting multiple genes associated with cancer in a single test.

Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments

Cancer screening represents the first line of defense in combating cancer, utilizing next-generation diagnostic technologies to identify the presence of cancer in individuals showing no apparent symptoms. This segment focuses on early cancer detection, aiming to diagnose diseases at a stage where they are more likely to be treated successfully. Advanced imaging technologies, molecular diagnostics, and biomarker assessment are tools used to enhance cancer screening efficacy. Companion diagnostics are specialized tests designed to identify patients most likely to benefit from a targeted therapy. This segment plays a critical role in personalized medicine by determining the presence of specific genetic or molecular markers that predict how well a patient will respond to targeted therapy options. In the context of next-generation cancer diagnostics, this often involves using genomic profiling to tailor treatment strategies to the individual's cancer. Prognostic tools in next-generation cancer diagnostics are employed to predict cancer's likely course and outcome in diagnosed patients. This segment helps in assessing disease aggression, the risk of recurrence, and overall survival expectations. By leveraging advanced genomic and proteomic analysis, prognostic diagnostics aid in making informed decisions regarding the necessity and intensity of therapeutic interventions, ultimately guiding patient management plans. Risk analysis in next-generation cancer diagnostics focuses on assessing an individual's risk of developing cancer based on genetic, environmental, and lifestyle factors. This segment utilizes various genetic testing and biomarker evaluation methods to identify individuals at higher risk for developing specific cancers, potentially leading to targeted preventive measures or more frequent and detailed surveillance programs. Therapeutic monitoring involves using next-generation diagnostic tools to track the effectiveness of cancer treatments and monitor for signs of disease progression or recurrence. This application segment is crucial for adjusting treatment plans in real time, managing side effects, and improving patient outcomes. Through the employment of circulating tumor DNA (ctDNA), imaging technologies, and other biomarkers, therapeutic monitoring provides detailed insights into the tumor's response to treatment and facilitates personalized treatment adjustments.

Regional Insights

In the Americas, particularly the United States, next-generation cancer diagnostics are experiencing rapid advancements, largely driven by significant investments in research and development. The focus is largely on precision medicine and non-invasive diagnostic techniques, such as liquid biopsies that detect circulating tumor DNA. The EMEA region shows a diverse landscape in adopting and developing next-generation cancer diagnostics. Europe leads within the region, with several countries incorporating genomic sequencing and biomarker analysis into standard cancer care, supported by strong healthcare systems and public healthcare policies. The Middle East, particularly countries such as Israel and the United Arab Emirates, are rapidly emerging as innovative hubs for medical technology, including cancer diagnostics. Africa faces more challenges, including resource limitations, but progress is being made through international partnerships and initiatives to improve cancer care infrastructure and accessibility. The Asia-Pacific region is witnessing significant growth in the next-generation cancer diagnostics market, driven by rising cancer prevalence, growing healthcare expenditure, and a surge in awareness about early cancer detection. Japan, South Korea, China, and Australia are at the forefront, investing heavily in healthcare technology and research. China, in particular, has seen rapid advancements and high adoption rates of technologies such as AI-driven diagnostic tools. Additionally, the region benefits from several fast-growing biotech startups and strategic collaborations between global and local firms aiming to tailor cancer diagnostics to regional specificities.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agena Bioscience, Inc. by Mesa Laboratories, Inc., Agilent Technologies, Inc., Akadeum Life Sciences, Almac Group, Becton, Dickinson & Company, Bio-Techne Corporation, Biological Dynamics Inc., bioMerieux SA, BioNTech SE, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., NeoGenomics Laboratories, Novartis AG, OPKO Health, Inc., Oxford Nanopore Technologies Limited, Perkin Elmer, Inc., Qiagen N.V., Siemens Healthineers AG, Sysmex Corporation, Telerad Tech, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
    • DNA Microarrays
    • Lab-on-a-Chip & Reverse Transcriptase-PCR
    • Molecular Diagnostics
    • Next Generation Sequencing
    • Protein Microarrays
    • qPCR & Multiplexing
  • Cancer Type
    • Bladder Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Kidney Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Thyroid Cancer
    • Uterine Cancer
  • Application
    • Cancer Screening
    • Companion Diagnostics
    • Prognostics
    • Risk Analysis
    • Therapeutic Monitoring
  • Function
    • Biomarker Development
    • CTC Analysis
    • Epigenetic Analysis
    • Genetic Analysis
    • Proteomic Analysis
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Next-Generation Cancer Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Cancer Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Next-Generation Cancer Diagnostics Market?

4. What is the market share of the leading vendors in the Next-Generation Cancer Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Next-Generation Cancer Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Burden of Cancer Cases Globally and Need for Efficient Diagnostics
      • 5.1.1.2. Growing Utilization of Microfluidic Chips in Cancer Management
      • 5.1.1.3. Government Initiatives Towards Cancer Screening
    • 5.1.2. Restraints
      • 5.1.2.1. High Investment and Insufficient Standardization of Diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Proliferation of Personalized and Advanced Genome Medicine
      • 5.1.3.2. Technological Advancements in Next-Generation Cancer Diagnostics
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations and Risks Associated with NGC Diagnostics
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Increasing demand across molecular diagnostics to identify mutations associated with cancer
    • 5.2.2. Application: Deployment of diagnostic tools across therapeutic monitoring to track the effectiveness of cancer treatments
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis
  • 5.9. Client Customization

6. Next-Generation Cancer Diagnostics Market, by Technology

  • 6.1. Introduction
  • 6.2. Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
  • 6.3. DNA Microarrays
  • 6.4. Lab-on-a-Chip & Reverse Transcriptase-PCR
  • 6.5. Molecular Diagnostics
  • 6.6. Next Generation Sequencing
  • 6.7. Protein Microarrays
  • 6.8. qPCR & Multiplexing

7. Next-Generation Cancer Diagnostics Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Bladder Cancer
  • 7.3. Breast Cancer
  • 7.4. Cervical Cancer
  • 7.5. Colorectal Cancer
  • 7.6. Kidney Cancer
  • 7.7. Lung Cancer
  • 7.8. Pancreatic Cancer
  • 7.9. Prostate Cancer
  • 7.10. Thyroid Cancer
  • 7.11. Uterine Cancer

8. Next-Generation Cancer Diagnostics Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer Screening
  • 8.3. Companion Diagnostics
  • 8.4. Prognostics
  • 8.5. Risk Analysis
  • 8.6. Therapeutic Monitoring

9. Next-Generation Cancer Diagnostics Market, by Function

  • 9.1. Introduction
  • 9.2. Biomarker Development
  • 9.3. CTC Analysis
  • 9.4. Epigenetic Analysis
  • 9.5. Genetic Analysis
  • 9.6. Proteomic Analysis

10. Americas Next-Generation Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Next-Generation Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Next-Generation Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Genialis to Develop Biomarker-Based Cancer Diagnostic Models
    • 13.3.2. Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
    • 13.3.3. Pfizer shifts focus to oncology with USD 43 billion Seagen acquisition
    • 13.3.4. Ibex and Alverno Laboratories Sign Multi-Year, Multi-Tissue Expansion Agreement of AI for Cancer Diagnosis
    • 13.3.5. Swansea biotech startup raises £1.5m for AI bowel cancer blood test
    • 13.3.6. Precision for Medicine Accelerating Precision Oncology with Next Generation Screening to Support New Cancer Diagnostics

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NEXT-GENERATION CANCER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 86. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 163. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 164. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 171. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 172. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 173. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 180. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 184. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 187. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 188. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 189. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 194. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 196. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 202. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 203. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 204. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 205. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 208. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 209. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 210. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 211. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 212. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 213. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 216. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 217. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 218. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 219. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 220. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 221. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 222. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 223. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 226. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 237. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 238. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 239. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 242. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 243. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 244. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 245. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 246. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 247. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 252. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 253. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 254. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 255. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 260. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 261. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 262. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 263. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 266. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 267. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 268. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 269. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 270. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 271. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 274. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 275. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 276. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 277. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 278. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 279. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 284. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 285. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 286. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 287. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 290. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 291. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2023 (USD MILLION)
  • TABLE 292. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2024-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
  • TABLE 294. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 298. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS